Dementia With Lewy Bodies is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Dementia with Lewy bodies (DLB) is a neurodegenerative dementia defined by progressive cognitive impairment together with core clinical features such as fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism[@mckeith2017][@gomperts2016]. Pathologically, DLB is linked to cortical and subcortical accumulation of misfolded alpha-synuclein, placing it within the broader Lewy body disease spectrum[@mckeith2017][@spillantini2000].
¶ Epidemiology and Risk Factors
¶ Prevalence and Incidence
DLB is the second most common neurodegenerative dementia after Alzheimer's disease, accounting for approximately 10-15% of all dementia cases at autopsy and 3-7% of community-diagnosed dementia[@vann2014][@dementia2025]. The prevalence increases with age, affecting approximately 0.1% of individuals aged 65-69 years and rising to 5-7% of those over 80 years[@vann2014]. DLB has a slight male predominance in some studies, though this varies by population[@dementia2025].
- Age: Primary risk factor, with incidence increasing substantially after age 65
- Genetics: Family history increases risk; specific risk alleles include:
- GBA gene variants (associated with increased risk)
- SNCA gene multiplications and variants
- APOE ε4 allele (particularly for AD comorbidity)
- Prodromal conditions: REM sleep behavior disorder (RBD) is a strong prodromal marker
- Vascular risk factors: May contribute to disease onset and severity
DLB is classified as a synucleinopathy characterized by the abnormal accumulation of misfolded alpha-synuclein protein in the form of Lewy bodies and Lewy neurites[@mckeith2017][@spillantini2000]. The distribution of pathology follows a staging system:
flowchart TD
A["Brainstem Nuclei"] --> B["Subcortical Structures"]
B --> C[" Limbic System"]
C --> D["Isocortex"]
A --> B --> C --> D
style A fill:#c8e6c9
style B fill:#FFD700
style C fill:#FFA500
style D fill:#FF4500
Lewy body staging (Braak):
- Stage 1-2: Dorsal motor nucleus of vagus, locus coeruleus, substantia nigra
- Stage 3-4: Limbic structures (amygdala, hippocampus, basal forebrain)
- Stage 5-6: Isocortical areas (association and primary cortices)
The pathogenesis of DLB involves several interconnected mechanisms:
- Alpha-synuclein misfolding: Native unfolded alpha-synuclein converts to toxic oligomers and fibrils
- Prion-like propagation: Misfolded protein spreads transsynaptically through neural circuits
- Neuroinflammation: Microglial activation contributes to neuronal dysfunction
- Synaptic dysfunction: Loss of synaptic proteins and impaired neurotransmission
- Cholinergic deficits: Severe loss of cholinergic neurons (nucleus basalis of Meynert)
- Dopaminergic dysfunction: Nigrostriatal pathway involvement
| Neurotransmitter |
Changes in DLB |
Clinical Correlation |
| Acetylcholine |
Severe cortical loss |
Cognitive impairment, visual hallucinations |
| Dopamine |
Nigrostriatal degeneration |
Parkinsonism |
| Serotonin |
Raphe nuclei involvement |
Depression, anxiety |
| Norepinephrine |
Locus coeruleus loss |
Autonomic dysfunction, attention |
DLB is diagnosed based on the presence of core clinical features. The diagnosis requires either:
- Two core features (without parkinsonism): sufficient for probable DLB
- One core feature (with parkinsonism): sufficient for probable DLB
1. Fluctuating Cognition
- Pronounced variations in attention and alertness
- Episodes lasting minutes to hours
- Often accompanied by marked daytime drowsiness
- May appear similar to delirium but without underlying precipitant
2. Recurrent Visual Hallucinations
- Typically occur in low-light or unfamiliar environments
- Often detailed, well-formed images of people or animals
- Frequently occur early in disease course
- May be responsive to cholinesterase inhibitors
- Can be induced or worsened by dopaminergic medications
3. Spontaneous Parkinsonism
- Bradykinesia plus at least one other: tremor, rigidity, or postural instability
- Similar to idiopathic Parkinson's disease but may be less severe
- Can develop before or after dementia onset
4. REM Sleep Behavior Disorder (RBD)
- Loss of REM sleep atonia
- Dream-enacting behaviors (punching, kicking, talking)
- Often precedes other symptoms by years to decades
- Strong association with synucleinopathies
- Reduced dopamine transporter uptake in basal ganglia on SPECT/PET
- Low uptake in occipital lobe on SPECT/PET
- Prominent hyposmia (loss of smell)
- Severe autonomic dysfunction (orthostatic hypotension, urinary incontinence)
- Delusions (often of jealousy, persecution, or misidentification)
- Hallucinations in other modalities (auditory, tactile, olfactory)
- Attention and executive deficits: Often prominent early
- Visuospatial impairment: May be more severe than in AD
- Memory: Relatively preserved compared to AD in early stages
- Language: Generally less impaired than AD initially
- Fluctuations: Can be profound, mimicking delirium
| Modality |
Finding |
Diagnostic Utility |
| DaT-SPECT |
Reduced dopamine transporter uptake in caudate/putamen |
Supports DLB vs AD |
| FDG-PET |
Occipital hypometabolism |
Supports DLB vs AD |
| MRI |
Relative hippocampal preservation vs AD |
Supports DLB |
| DAT-PET |
Reduced striatal binding |
Supports DLB |
- Alpha-synuclein seed amplification assay: Detects pathological alpha-synuclein
- Total tau: May be elevated but less than AD
- Amyloid-beta 1-42: May be normal or mildly reduced (unlike AD)
- Neurofilament light chain (NfL): Elevated in both DLB and AD
¶ Autopsy and Tissue Biomarkers
- Cortical and limbic Lewy bodies (alpha-synuclein positive)
- Lewy neurites in hippocampal CA2/3 regions
- Variable AD co-pathology (30-50% of cases)
- Neuronal loss in substantia nigra and locus coeruleus
The 2017 consensus criteria from the DLB Consortium provide the standard diagnostic framework[@mckeith2017]:
Probable DLB:
- Two or more core clinical features
- OR one core feature plus one or more suggestive features
Possible DLB:
- One core clinical feature
- OR one or more suggestive features
Parkinson's Disease Dementia (PDD):
- DLB: Dementia onset occurs before or within 1 year of parkinsonism
- PDD: Dementia develops after established Parkinson's disease (typically >1 year)
- Both have similar pathophysiology and may represent a spectrum
Alzheimer's Disease:
- AD: Prominent early memory impairment, hippocampal atrophy
- DLB: Fluctuating cognition, visual hallucinations early, relative memory preservation
- Both can have co-pathology (~30-50% of DLB cases)
Other Dementias:
- Vascular dementia: Stepwise progression, focal neurological signs
- Frontotemporal dementia: Prominent behavioral changes, early personality changes
- Normal pressure hydrocephalus: Gait disturbance, urinary incontinence, dementia
| Feature |
DLB |
AD |
PDD |
| DaT scan |
Abnormal |
Normal |
Abnormal |
| Occipital metabolism |
Reduced |
Normal |
Variable |
| Hippocampal atrophy |
Mild/moderate |
Severe |
Variable |
| CSF amyloid |
Normal/reduced |
Abnormal |
Variable |
Cholinesterase Inhibitors:
- Donepezil and rivastigmine are first-line treatments
- Improve cognitive function and reduce hallucinations
- Evidence stronger than for AD in some studies
- Generally well-tolerated
Memantine:
- May provide modest cognitive benefits
- Often used in combination with cholinesterase inhibitors
Dopaminergic Agents:
- Levodopa may improve parkinsonism but can worsen hallucinations
- Start low, go slow approach recommended
- Dopamine agonists more likely to induce psychosis
Antipsychotics:
- AVOID typical antipsychotics (haloperidol) - can cause severe reactions
- Pimavanserin (5-HT2A inverse agonist) - FDA approved for PD psychosis
- Quetiapine may be used with caution
- Environmental modifications: Reduce clutter, improve lighting, use contrast
- Caregiver education: Understanding fluctuations and hallucinations
- Sleep hygiene: Manage RBD, protect bed partner
- Exercise: Physical therapy for mobility and fall prevention
- Cognitive stimulation: Structured activities, routines
| Symptom |
First-line Treatment |
Notes |
| Cognitive impairment |
Cholinesterase inhibitors |
Donepezil, rivastigmine |
| Visual hallucinations |
Cholinesterase inhibitors, pimavanserin |
Avoid typical antipsychotics |
| Parkinsonism |
Levodopa |
Start low, monitor for psychosis |
| RBD |
Melatonin, clonazepam |
Safety measures for bed partner |
| Depression |
SSRIs |
Avoid anticholinergics |
| Autonomic dysfunction |
Supportive care, midodrine |
Compression stockings |
¶ Research and Clinical Trials
Disease-modifying therapies targeting alpha-synuclein:
- Immunotherapy (active and passive vaccination)
- Small molecule aggregation inhibitors
- Gene therapy approaches
- Neuroprotective agents
| Agent |
Mechanism |
Phase |
Target |
| ACI-35 |
Self-assembling liposome vaccine |
Phase 1b |
alpha-synuclein |
| SB-220 |
P2X7 antagonist |
Phase 2 |
Neuroinflammation |
| NB-2001 |
MT5-MMP inhibitor |
Phase 1 |
alpha-synuclein clearance |
Seed amplification assays (RT-QuIC, PMCA) have shown significant advances in DLB diagnosis[@paillusson2025]:
- Sensitivity: 90-95% for detecting DLB in CSF
- Specificity: 85-95% for distinguishing from AD
- Clinical utility: Now recommended in 2025 consensus guidelines as supportive biomarker
- Blood-based testing: Emerging as less invasive alternative to CSF testing
The 2025 A/T/N biomarker framework application in DLB has clarified AD comorbidity[@birmingham2025]:
- Amyloid-positive DLB: ~50-60% of cases show co-existing amyloid pathology
- Tau biomarker patterns: DLB shows intermediate tau levels between AD and controls
- Impact on prognosis: Amyloid-positive DLB shows faster progression
- Treatment implications: Cholinesterase inhibitors effective regardless of AD comorbidity
Longitudinal plasma NfL studies in DLB show distinct patterns[@mak2025]:
- DLB shows higher baseline NfL than controls but lower than AD
- Rapid progression: Elevated NfL correlates with faster cognitive decline
- Utility: NfL trajectory helpful for prognosis and clinical trial enrichment
- Comparison with AD: Different slope patterns aid differential diagnosis
¶ Lewy Body Staging (2025 Revision)
The updated staging system refines the Braak model for DLB[@zaccai2025]:
- Brainstem-predominant: Earlier cognitive impairment than expected
- Cortical-first pattern: Some DLB cases show cortical involvement before brainstem
- Network-based staging: Pathology follows functional connectivity networks
- Clinical correlation: Staging predicts symptom profile and progression rate
Recommendations for DLB clinical trials[@gomperts2025]:
- Primary endpoints: Cognitive measures (MMSE, CDR) combined with functional scales
- Secondary endpoints: Motor assessments, neuropsychiatric inventory, quality of life
- Biomarker endpoints: NfL, alpha-synuclein seed amplification as exploratory markers
- Duration: Minimum 52 weeks recommended for disease-modifying trials
-
McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
-
Walker Z et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78(5):1176-1181.
-
Spillantini MG et al. Alpha-synuclein in Lewy bodies. Nature. 2000;388(6645):839-840.
-
Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673-683.
-
Gomperts SN. Lewy Body Dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435-463.
- McKeith IG et al, Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium (2017)
- Gomperts SN, Lewy Body Dementia (2016)
- Spillantini MG et al, Alpha-synuclein in Lewy bodies (2000)
- Vann Jones SA, O'Brien JT, The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies (2014)
- Dementia With Lewy Bodies (2025)
- Paillusson et al, Alpha-synuclein seed amplification assay performance in Dementia with Lewy Bodies (2025)
- Birmingham et al, DLB and AD biomarker overlap: A/T/N framework application in Lewy body disease (2025)
- Mak et al, Longitudinal plasma NfL trajectories in DLB: Comparison with Alzheimer's disease (2025)
- Gomperts et al, Clinical trial endpoints in Dementia with Lewy Bodies: Consensus recommendations (2025)
- Zaccai et al, Lewy body staging: 2025 revision of the Braak system for DLB (2025)